The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study

  • Background: Tetracyclines and clindamycin plus rifampicin combination therapy are both considered first-line therapy in current hidradenitis suppurativa guidelines. However, evidence for their efficacy is drawn from small studies, often without validated outcomes. Objective: To assess the 12-week efficacy of oral tetracyclines and a combination of clindamycin and rifampicin. Methods: A prospective, international cohort study performed between October 2018 and August 2019. Results: In total, 63.6% of the included 283 patients received oral tetracyclines, and 36.4% were treated with clindamycin and rifampicin. Both groups showed a significant decrease in International Hidradenitis Suppurativa Severity Score System from baseline (both P < .001). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 40.1% and 48.2% of patients, respectively (P = .26). Patient characteristics or disease severity were not associated with the attainment of HiSCR or the minimal clinically important differences for the Dermatology Life Quality Index and pain. Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients had to be excluded from the HiSCR analysis for the tetracycline and combination therapy group because of a low abscess and nodule count at baseline. Conclusion: This study shows significant efficacy of both tetracycline treatment and clindamycin and rifampicin combination therapy after 12 weeks in patients with hidradenitis suppurativa. No significant differences in efficacy were observed between the 2 treatments, regardless of disease severity.

Download full text files

Export metadata

Metadaten
Author:Kelsey R. van StraalenORCiD, Thrasyvoulos Tzellos, Phillipe Guillem, Farida BenhadouORCiD, Carlos Cuenca-BarralesORCiD, Mathilde Daxhele, Mathieu DaoudORCiD, Ourania EfthymiouORCiD, Evangelos J. Giamarellos-BourboulisORCiDGND, Gregor B. E. JemecORCiDGND, Alexandros KatoulisORCiD, Anke KönigGND, Elizabeth LazaridouORCiD, Angelo V. MarzanoORCiD, Łucas Matusiak, Alejandro Molina-LeyvaORCiD, Chiara MoltrasioORCiD, Andreas PinterORCiDGND, Concetta PotenzaORCiD, Jorge RomaníORCiD, Ditte M. SaunteORCiD, Nevena SkrozaORCiD, Dimitra Stergianou, Jacek C. SzepietowskiORCiDGND, Anastasia TrigoniORCiD, Eva VilarrasaORCiD, Hessel H. van der ZeeORCiD
URN:urn:nbn:de:hebis:30:3-630895
DOI:https://doi.org/10.1016/j.jaad.2020.12.089
ISSN:1097-6787
Parent Title (English):Journal of the American Academy of Dermatology
Publisher:Elsevier
Place of publication:Amsterdam [u.a.]
Document Type:Article
Language:English
Date of Publication (online):2021/01/20
Date of first Publication:2021/01/20
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/07/04
Tag:acne inversa; antibiotics; clindamycin; doxycycline; efficacy; guideline; minocycline; outcome; rifampicin; tetracycline; therapy; treatment
Volume:85.2021
Issue:2
Page Number:10
First Page:369
Last Page:378
HeBIS-PPN:502117982
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0